Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis

J Neuroimmunol. 2012 Oct 15;251(1-2):45-54. doi: 10.1016/j.jneuroim.2012.07.003. Epub 2012 Jul 28.


Laquinimod is an orally administered drug under development for the treatment of Multiple Sclerosis (MS), lacking a fully elucidated mode of action. We assessed the immunomodulatory effects of laquinimod in vitro on human B cells from healthy or MS patients, cultured alone or with CD4(+) T cells. Laquinimod modulated B cell markers, mainly by increasing the regulatory ones CD25, IL10 and CD86, and decreased IL4, while increasing IL10 and TGFβ in both B and T cells, in a B cell-mediated manner. These findings shed additional light on the mechanisms underlying the effects of laquinimod in MS and potentially other immune-mediated diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • B-Lymphocytes / drug effects*
  • B7-2 Antigen / biosynthesis
  • Cells, Cultured
  • Coculture Techniques
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Interleukin-10 / biosynthesis
  • Interleukin-2 Receptor alpha Subunit / biosynthesis
  • Interleukin-4 / biosynthesis
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Quinolones / therapeutic use*
  • T-Lymphocytes / drug effects
  • Transforming Growth Factor beta / biosynthesis
  • Young Adult


  • B7-2 Antigen
  • IL10 protein, human
  • IL2RA protein, human
  • IL4 protein, human
  • Immunologic Factors
  • Interleukin-2 Receptor alpha Subunit
  • Quinolones
  • Transforming Growth Factor beta
  • Interleukin-10
  • Interleukin-4
  • laquinimod